 One measurement of an HIV infected persons risk of progressing to AIDS is the number of viral particles of HIV in their blood called a viral load. In a previous phase III study, SP01A was observed to significantly lower the amount of HIV in blood, improve quality of life how well subjects felt, have a favorable safety profile minimal side effects, and be well tolerated. Moreover, in in vitro testing SP01A: 1 demonstrated comparable or greater efficacy than currently approved anti-HIV drugs in preventing HIV virus replication; 2 was observed to have minimal toxic effect on human cells; and 3 demonstrated significant efficacy in preventing virus replication of HIV virus strains that resist currently approved anti-HIV treatments. Based on these results, SP01A demonstrates promise as a new and novel anti-HIV treatment. 